- Home
- BNGO vs MBRX Comparison
BNGO vs MBRX Comparison
Compare BNGO & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNGO
- MBRX
- Stock Information
- Founded
- BNGO 2003
- MBRX 2015
- Country
- BNGO United States
- MBRX United States
- Employees
- BNGO N/A
- MBRX N/A
- Industry
- BNGO Biotechnology: Laboratory Analytical Instruments
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- BNGO Industrials
- MBRX Health Care
- Exchange
- BNGO Nasdaq
- MBRX Nasdaq
- Market Cap
- BNGO 24.3M
- MBRX 23.5M
- IPO Year
- BNGO 2018
- MBRX 2016
- Fundamental
- Price
- BNGO $1.95
- MBRX $0.47
- Analyst Decision
- BNGO Buy
- MBRX Strong Buy
- Analyst Count
- BNGO 4
- MBRX 4
- Target Price
- BNGO $7.67
- MBRX $5.00
- AVG Volume (30 Days)
- BNGO 1.6M
- MBRX 2.6M
- Earning Date
- BNGO 11-12-2025
- MBRX 11-07-2025
- Dividend Yield
- BNGO N/A
- MBRX N/A
- EPS Growth
- BNGO N/A
- MBRX N/A
- EPS
- BNGO N/A
- MBRX N/A
- Revenue
- BNGO $27,426,000.00
- MBRX N/A
- Revenue This Year
- BNGO N/A
- MBRX N/A
- Revenue Next Year
- BNGO $24.54
- MBRX N/A
- P/E Ratio
- BNGO N/A
- MBRX N/A
- Revenue Growth
- BNGO N/A
- MBRX N/A
- 52 Week Low
- BNGO $1.50
- MBRX $0.25
- 52 Week High
- BNGO $25.65
- MBRX $3.65
- Technical
- Relative Strength Index (RSI)
- BNGO 39.67
- MBRX 49.51
- Support Level
- BNGO $1.63
- MBRX $0.42
- Resistance Level
- BNGO $2.15
- MBRX $0.52
- Average True Range (ATR)
- BNGO 0.12
- MBRX 0.04
- MACD
- BNGO 0.08
- MBRX 0.01
- Stochastic Oscillator
- BNGO 60.64
- MBRX 41.41
About BNGO Bionano Genomics Inc.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.